Update - April 11th, 2019
Last week, the United Kingdom (UK) and European Union (EU) reached an agreement on a postponement of the Brexit after ample discussions. As a result, the Brexit will not occur on Friday, March 29, 2019 as originally planned.
Actually today, March 29th, 2019, on the day the UK was due to leave the EU, MPs will have a third vote on the Withdrawal Agreement - the legally binding document that sets out the terms of the UK's departure from the EU. This includes a settlement, details of a transition period for after the UK leaves and protections for citizens' rights. It also includes the controversial backstop, or the insurance policy that aims to prevent a hard border returning to the island of Ireland.
Eurofins BioPharma Services looks forward to meeting you at the ProcureCon PHARMA meeting in Frankfurt, Germany from March 19-20, 2019.
The deadline for the United Kingdom to withdraw from the European Union, known as Brexit, is quickly approaching. The formal date will be March 29, 2019. In June 2016, Britain held a national referendum on their European Union membership, and having to choose between remain and leave, the British voted to leave by 52%. After 18 months of negotiating a divorce plan on trade, security and migration matters with European Union, the deal was rejected by the British Parliament just 10 weeks before Britain is scheduled to leave the EU.
The GLP (Good Laboratory Practice) Testing Facility of Eurofins Central Laboratory in Breda, The Netherlands has been accredited for OECD GLP for over 30 years. It all started at the BCO Centre for Research (B for Bergschot 71, the street address ever since) with the first inspection by the Dutch Health Care Inspectorate in June 1988. Over the years, BCO underwent several transformations and evolved into becoming one of the Eurofins Central Laboratory facilities, keeping the GLP Test Facility embedded in the Breda Clinical Laboratory.
Surgeons worldwide perform more than 100,000 solid organ transplants annually, with successful transplantation of hearts, lungs, livers and kidneys saving and changing thousands of lives. After complex surgery, the risks of infection and organ transplant rejection mean the patient’s fight for recovery starts immediately; even anti-rejection medication can lead to serious adverse effects. Eurofins’ work in immunity is helping to change patient recovery outcomes.
Eurofins Central Laboratory, a member of the leading international Eurofins Scientific Group, announced today that it will extend its capabilities in global Kit Packing and Distribution Services by opening a Good Manufacturing Practices (GMP) compliant Kit Packing and Distribution facility in Louisville, KY, US.
Tags: Kits & Logistics